2160 Stock Overview
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
GNI Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥2,490.00 |
| 52 Week High | JP¥3,865.00 |
| 52 Week Low | JP¥998.00 |
| Beta | 1.37 |
| 1 Month Change | -17.96% |
| 3 Month Change | -8.19% |
| 1 Year Change | 146.78% |
| 3 Year Change | 22.66% |
| 5 Year Change | 148.17% |
| Change since IPO | 768.60% |
Recent News & Updates
Is GNI Group (TSE:2160) Using Too Much Debt?
Apr 12
News Flash: Analysts Just Made An Incredible Upgrade To Their GNI Group Ltd. (TSE:2160) Forecasts
Mar 19Further Upside For GNI Group Ltd. (TSE:2160) Shares Could Introduce Price Risks After 40% Bounce
Feb 28Shareholder Returns
| 2160 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | -1.7% | 1.2% | -1.0% |
| 1Y | 146.8% | -26.2% | 27.9% |
Return vs Industry: 2160 exceeded the JP Biotechs industry which returned -26.2% over the past year.
Return vs Market: 2160 exceeded the JP Market which returned 27.9% over the past year.
Price Volatility
| 2160 volatility | |
|---|---|
| 2160 Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 8.1% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in JP Market | 8.1% |
| 10% least volatile stocks in JP Market | 2.2% |
Stable Share Price: 2160's share price has been volatile over the past 3 months.
Volatility Over Time: 2160's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 843 | Ying Luo | www.gnipharma.com |
GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy.
GNI Group Ltd. Fundamentals Summary
| 2160 fundamental statistics | |
|---|---|
| Market cap | JP¥124.20b |
| Earnings (TTM) | JP¥8.09b |
| Revenue (TTM) | JP¥26.01b |
15.3x
P/E Ratio4.8x
P/S RatioIs 2160 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2160 income statement (TTM) | |
|---|---|
| Revenue | JP¥26.01b |
| Cost of Revenue | JP¥3.58b |
| Gross Profit | JP¥22.43b |
| Other Expenses | JP¥14.34b |
| Earnings | JP¥8.09b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 162.27 |
| Gross Margin | 86.24% |
| Net Profit Margin | 31.12% |
| Debt/Equity Ratio | 9.2% |
How did 2160 perform over the long term?
See historical performance and comparison